← 治験一覧に戻る
鼻茸を伴う慢性副鼻腔炎の日本人患者におけるデュピルマブの有効性（SINUS-M52）
基本情報
- NCT ID
- NCT05049122
- ステータス
- 完了
- 試験のフェーズ
- 第4相
- 試験タイプ
- 介入
- 目標被験者数
- 25
- 治験依頼者名
- Sanofi
概要
This was a Phase 4, open-label, single-arm, multicenter study to evaluate the efficacy and safety of dupilumab subcutaneous (SC) injection monotherapy in Japanese participants aged 18 or older with CRSwNP that is not adequately controlled with existing therapies. Duration of study period (per participant): * Screening Period (2 to 4 weeks) * Intervention Period (up to 52 weeks±3 days)
対象疾患
Chronic Rhinosinusitis With Nasal Polyps
介入
Dupilumab SAR231893(DRUG)